In addition to passively accumulating at sites of inflammation and malignant disease, LNP delivery systems are naturally taken up by cells of the immune system following systemic administration. For this reason, our researchfocuses on using LNP to enhance the delivery of immunostimulatory oligodeoxynucleotides containing CpG motifs to antigen presenting cells. This work is aimed at stimulating the innate immune system to improve the potency of monoclonal antibodies in cancer therapy as well as developing more effective vaccine adjuvants for use against infectious and malignant disease.